The impact of a disease management program (COACH) on the attainment of better cardiovascular risk control in dyslipidaemic patients at primary care centres (The DISSEMINATE Study): a randomised controlled trial

  • Francis Jude Selvaraj1Email author,

    Affiliated with

    • Mafauzy Mohamed2,

      Affiliated with

      • Khairani Omar3,

        Affiliated with

        • Sudha Nanthan4,

          Affiliated with

          • Zainab Kusiar5,

            Affiliated with

            • Selvaraj Y Subramaniam6,

              Affiliated with

              • Norsiah Ali7,

                Affiliated with

                • Kamalakaran Karanakaran8,

                  Affiliated with

                  • Fauziah Ahmad9,

                    Affiliated with

                    • Wilson H H Low10 and

                      Affiliated with

                      • of the DISSEMINATE study group

                        Affiliated with

                        BMC Family Practice201213:97

                        DOI: 10.1186/1471-2296-13-97

                        Received: 2 May 2012

                        Accepted: 5 October 2012

                        Published: 10 October 2012



                        To evaluate the efficacy of Counselling and Advisory Care for Health (COACH) programme in managing dyslipidaemia among primary care practices in Malaysia. This open-label, parallel, randomised controlled trial compared the COACH programme delivered by primary care physicians alone (PCP arm) and primary care physicians assisted by nurse educators (PCP-NE arm).


                        This was a multi-centre, open label, randomised trial of a disease management programme (COACH) among dyslipidaemic patients in 21 Malaysia primary care practices. The participating centres enrolled 297 treatment naïve subjects who had the primary diagnosis of dyslipidaemia; 149 were randomised to the COACH programme delivered by primary care physicians assisted by nurse educators (PCP-NE) and 148 to care provided by primary care physicians (PCP) alone. The primary efficacy endpoint was the mean percentage change from baseline LDL-C at week 24 between the 2 study arms. Secondary endpoints included mean percentage change from baseline of lipid profile (TC, LDL-C, HDL-C, TG, TC: HDL ratio), Framingham Cardiovascular Health Risk Score and absolute risk change from baseline in blood pressure parameters at week 24. The study also assessed the sustainability of programme efficacy at week 36.


                        Both study arms demonstrated improvement in LDL-C from baseline. The least squares (LS) mean change from baseline LDL-C were −30.09% and −27.54% for PCP-NE and PCP respectively. The difference in mean change between groups was 2.55% (p=0.288), with a greater change seen in the PCP-NE arm. Similar observations were made between the study groups in relation to total cholesterol change at week 24. Significant difference in percentage change from baseline of HDL-C were observed between the PCP-NE and PCP groups, 3.01%, 95% CI 0.12-5.90, p=0.041, at week 24. There was no significant difference in lipid outcomes between 2 study groups at week 36 (12 weeks after the programme had ended).


                        Patients who received coaching and advice from primary care physicians (with or without the assistance by nurse educators) showed improvement in LDL-cholesterol. Disease management services delivered by PCP-NE demonstrated a trend towards add-on improvements in cholesterol control compared to care delivered by physicians alone; however, the improvements were not maintained when the services were withdrawn.

                        Trial registration

                        National Medical Research Registration (NMRR) Number: NMRR-08-287-1442

                        Trial Registration Number ( Identifier): NCT00708370


                        Dyslipidaemia Disease management Patient support Cardiovascular risk control


                        Chronic diseases pose a significant disease burden causing 60% of all deaths worldwide [1]. Of these, 50% are attributed to cardiovascular diseases [1]. Low-and middle-income countries are the biggest contributors to the increase in cardiovascular disease burden [2]. Although it varies among countries, the factors contributing to the escalating prevalence of chronic diseases are an ageing population, tobacco use, unhealthy diet practices and physical inactivity, urbanisation and global marketing [3], where half of these risk factors are modifiable through behaviour modification.

                        Primary healthcare plays a pivotal role in gearing patients towards positive behaviour management [4]. This can be achieved through the use of a chronic disease management (CDM) model, which emphasises the integration of several elements including multidisciplinary care delivery, patient education and provider decision support, self-management and patient empowerment support, clinical information technology, social support and quality incentives within the primary health care system [5]. Although studies have shown that chronic disease management are associated with marked improvements in many clinical outcomes associated with cardiovascular diseases [69]; many developing countries have yet to integrate CDM into their primary healthcare systems due to limited resources and systems orientated towards acute symptomatic care [4]. In addition, there is paucity of literature that addresses the sustainability of chronic disease management programmes in developing countries, in terms of its efficacy and cost.

                        Malaysia is not immune to the rising tide of chronic diseases, where cardiovascular diseases account for more than 25% of all-cause mortality [10] and prevalence of cardiovascular risk factors such as hypertension, diabetes mellitus and dyslipidaemia has reached epidemic proportions [11]. As a developing country, Malaysia is faced with the expected challenges of implementing chronic disease management in a resource-limited environment [12]. Although there have been several disease management programmes implemented in Malaysia, evidence on their cost-effectiveness, applicability and sustainability is lacking [13]. Despite the often-repeated recommendations to incorporate multidisciplinary healthcare teams in chronic disease care, access to allied health services is usually limited in a developing country like Malaysia. In addition, evidence to support the use of nurse-assisted dyslipidaemia management has been conflicting [14, 15].

                        In view of the current lack of evidence on CDM efficacy in a developing country such as Malaysia, we designed a randomised controlled trial to assess the impact of a chronic disease management programme, COACH (Counselling and Advisory Care for Health) in managing dyslipidaemia. The COACH programme used in this study was intended to be modelled after the original COACH study [16, 17]; however it was adjusted to the local situation and limitations. The primary objective of the DISSEMINATE study was to evaluate the efficacy of the COACH programme led by primary care physicians with assistance from nurse educators (PCP-NE) compared to that led by the primary care physicians alone (PCP) in improving serum low density level-cholesterol (LDL-C) in dyslipidaemic subjects over a period of 24 weeks. Secondary objectives included the impact of the COACH programme in the two arms in improving (i) patients’ lipid profiles i.e. High Density Lipoprotein-Cholesterol (HDL-C), LDL-C, Total Cholesterol (TC), Triglycerides (TG) and TC: HDL ratio, (ii) blood pressure (systolic and diastolic), (iii) Framingham cardiovascular risk, (iv) lifestyle modification (smoking behaviour, diet, alcohol consumption, physical activity), (v) programme satisfaction using a visual analogue scale (VAS) and (vi) statin compliance. All outcomes were assessed at 24 and 36 weeks of study duration. The outcomes assessment at 36 weeks was designed to evaluate the sustainability of programme effectiveness after the programme ended at week 24.


                        Trial design

                        This was a multi-centre, open-label, parallel, randomised trial of a disease management programme (COACH) led by primary care physicians for dyslipidaemic patients. Comparison was made between primary care physicians who managed patients alone (PCP Group-Control arm) versus those who were assisted by nurse educators (PCP-NE Group-Intervention arm). Patients were allocated on a 1:1 ratio. The study was approved by Malaysian Medical Research Ethics Committee (MREC) (National Medical Research Registration (NMRR) Number: NMRR-08-287-1442) and was conducted in compliance with the Declaration of Helsinki and International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines, as well as local regulatory requirements. No major changes were made to the trial methodology after study initiation.

                        Site selection

                        Sites were selected based on their ability to recruit patients and to commit to the project. In order to achieve the recruitment rate and to provide a fair representation of the patient population in Peninsula Malaysia, licensed primary healthcare centres around the Klang Valley and other suburban towns were invited. Other recruitment factors were availability of infrastructure such as internet line or fax machine, the investigator’s understanding of GCP, the availability of a site coordinator and previous clinical trial experience. Thirty five sites were approached and 21 sites actively participated in the study.

                        Subject recruitment

                        Patients who enrolled were newly diagnosed with dyslipidaemia. Subjects could be either male or female age 18 years or older. Besides having given informed consent, subjects must have been contactable via telephone, live or through short messaging services (SMS). Communication with patients through these methods was a key element of the COACH programme. Exclusion criteria applied included participation in any other clinical research studies in the preceding 6 months, history of mental illness, hypothyroidism, or presence of any other condition, which the investigators judged could increase risk to the subject and could interfere with the conduct of the study or interpretation of the data.

                        Eligibility was defined by dyslipidaemia divided according to 3 cardiovascular risk groups. Group I subjects were dyslipidaemic with an LDL-C level within 160 to 250mg/dL without concomitant cardiovascular risk factors. Group II subjects had at least one additional cardiovascular risk factor, excluding coronary heart disease (CHD) and diabetes mellitus (DM) with serum LDL-C level between 130 to 250mg/dL; Group III subjects consisted of those with serum LDL-C level between 100 to 250mg/dL with pre-existing CHD or CHD risk equivalent, such as DM or other atherosclerotic diseases. The study subjects were required to be lipid drug naïve and eligible for statin therapy prior to study enrolment. Random numbers were generated by computer and printed in sealed envelopes. The envelopes were subsequently allocated to each new patient enrolled into the programme. A person independent of the study was tasked to assign a randomisation number to a subject with known study identification number. The allocation of the individual study group was then made known when the envelopes were unveiled. Since COACH was administered by the nurse educators independent of the primary care doctor, knowledge of treatment allocation only became evident to the doctor when the subject returned for his/her third scheduled visit (week 12). The study duration was 36 weeks.

                        Study procedure

                        All subjects received standard care and advice from their primary care physicians as per the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel [ATP] III) guidelines [18]. As part of the standard care, all subjects received a COACH health booklet which was completed by the investigator during clinic visits. Subjects were expected to attend clinic visits at week 12, 24 and 36 after baseline randomisation. Statin dose was titrated according to cardiovascular risk group as recommended by NCEP ATP III Guidelines. Demographic data, primary diagnosis, medical history, family history, smoking status, alcohol, diet, physical activity, drug allergies and all other concomitant medications were captured in the study case report form (CRF). Blood pressure reading, pulse rate, general physical examination, 12-lead ECG, and blood sampling were also conducted during study visits. All blood samples were sent to a central laboratory for analysis. Telephone follow-up were made by site coordinators at week 6 and 18 to ensure all patients completed the health booklet correctly and complied with statin treatment. Subject compliance to prescribed statin was assessed by the primary care doctor and percentage compliance was noted in the CRF.

                        Study intervention

                        In addition to the standard care, subjects randomised to the PCP-NE COACH Programme received bi-weekly telephone follow-up by trained nurse educators for 24 weeks. The main purpose of the telephone call was to provide patient’s self-management support and patient empowerment and the discussion was guided by the health education booklet. During the telephone follow-up, the nurse educators provided reinforcement of the health education information and reminded patients to adhere to counselling advice and prescribed medications, as well as to discuss any problems of adherence encountered with their physicians. Each telephone call lasted an average of 15 min. Subjects also received phone calls and SMS to remind them about forthcoming follow-up visits. The study intervention was designed to support the doctor-patient relationship and reinforce the prescribed care plan.

                        Study control

                        All subjects randomised to PCP COACH Programme only received care from the site investigators as per normal practice. There was no additional telephone follow-up and reinforcement by nurse educators. At the end of 24 weeks, the study period ended. However, all subjects were required to attend follow-up visit at week 36, an extension phase, during which both arms received standard care only. This was to evaluate whether there would be sustained lipid control without reinforcement.

                        Outcome measures

                        The primary efficacy endpoint was the mean percentage change from baseline LDL-C at week 24 between the two treatment arms. Other efficacy endpoints included mean percentage change from baseline of lipid profile (TC, LDL-C, HDL-C, TG, TC: HDL ratio), Framingham Cardiovascular Heart Risk Score, and absolute risk change from baseline in blood pressure parameters (systolic and diastolic) at week 24 and week 36. Lifestyle change assessment of smoking behaviour, food consumption, physical activity, alcohol consumption, and medication compliance were also evaluated at the end of the study.

                        Statistical analysis

                        The sample size was calculated to detect a clinically meaningful difference of 10% in percentage change from baseline in LDL-C levels with a standard deviation of 22.5%, a 2-sided, 5% significance level and 85% power. During the implementation of the study, it was found that there was potential treatment contamination of the standard care arm where, behaviour modification occurred due to subjects from both arms interacting with each other. To overcome this, the sample size was adjusted to account 20% of treatment contamination (changing the effect size to 0.08%) and 10% attrition rate, giving the study a total of 320 subjects.

                        The analysis was conducted using intention-to-treat (ITT) analysis, which was defined as all lipid drug naïve subjects who were newly diagnosed with dyslipidaemia, eligible for statin therapy and were randomised with at least 1 post-baseline response (efficacy or outcomes research endpoints). Last observation carried forward was used for missing data in the ITT analysis.

                        Statistical analysis was based on the mean percentage change from baseline using a restricted maximum likelihood (REML) model with repeated measures approach (mixed model repeated measures [MMRM]). Significance tests were based on the least squares (LS) mean difference between treatment group to compare treatment contrast for week 24 and week 36. The analyses conducted at 24 weeks evaluated the effectiveness of the programme while analyses at 36 weeks assessed the medium-term effectiveness of care by physicians assisted by nurse educator (PCP-NE) compared with primary care physician care alone (PCP).


                        In order to achieve a sample size of 320 subjects, 364 potential subjects were screened however, only 297 subjects met the eligible criteria and were randomised. The period of patient recruitment was from September 2008 to July 2009. All patients were followed up for 36 weeks and the study was concluded in May 2010. One hundred and forty nine subjects were randomised to the PCP-NE COACH programme (Intervention) and 148 subjects to PCP COACH group (control). Of these, 122 (81.9%) from the intervention group and 123 (83.1%) from the standard care group completed the 36 weeks study. Figure 1 illustrates the trial profile for the DISSEMINATE study.
                        Figure 1

                        Study trial profile.

                        There were no significant differences in subjects’ baseline demographic characteristics and cardiovascular risk factors (Table 1). All subjects had a primary diagnosis of dyslipidaemia with a mean duration of 0.6 years from disease onset in both groups. All subjects were prescribed with HMG-CoA reductase inhibitors (statins). The most common statins prescribed in each group were lovastatin, simvastatin and atorvastatin. The median duration of statin treatment was 246 days. Approximately 99% and 95% of the patients in the intervention and control arm respectively reported compliance to statin treatment.
                        Table 1

                        Baseline subjects demographics & characteristics


                        Intervention Arm (n=149)

                        Control Arm (n=145)

                        Number of subjects; n (%)


                        86 (57.7%)

                        83 (57.2%)


                        63 (42.3%)

                        62 (42.8%)

                        Age, years; Mean (SD)

                        49.4 (11.1)

                        48.8 (9.9)

                        Race; Asian

                        149 (100.0)

                        145 (100.0)

                        Weight, kg; Mean(SD)

                        72.7 (15.2)

                        70.2 (15.1)

                        Height, cm; Mean (SD)

                        160.2 (8.2)

                        159.6 (9.3)

                        Body mass index, kg/m2; Mean (SD)

                        28.2 (4.9)

                        27.4 (4.9)

                        Mean duration of dyslipidaemia since onset (years)



                        Cardiovascular risk group a; n (%)

                           Group I

                        14 (9.4)

                        24 (16.6)

                           Group II

                        87 (58.4)

                        74 (51.0)

                           Group III

                        48 (32.2)

                        47 (32.4)

                        Age risk; n (%)

                           Male aged >45; Female aged >55

                        72 (48)

                        60 (41)

                           Male aged ≤45; Female aged ≤55

                        77 (52)

                        85 (59)

                        Family history b; n (%)


                        29 (19)

                        32 (22)


                        120 (81)

                        113 (78)

                        Blood pressure ≥ 140/90 mm Hg or antihypertensive medication at baseline; n (%)


                        89 (60)

                        88 (61)


                        60 (40)

                        57 (39)

                        Diabetes Mellitus; n (%)


                        47 (32)

                        47 (32)


                        102 (68)

                        98 (68)

                        CHD or CHD risk equivalent a; n (%)


                        1 (1)

                        1 (1)


                        148 (99)

                        144 (99)

                        Smoking Status

                           Never smoked

                        101 (68)

                        97 (67)


                        13 (9)

                        19 (13)

                           Current smoker

                        35 (23)

                        29 (20)

                        COACH = Counselling and Advisory Care for Health; SD = standard deviation; CHD = coronary heart disease; PCP = Primary Care Physicians; PCP-NE = Primary Care Physicians assisted by Nurse Educators.

                        a Group I: subjects with dyslipidaemia with no other cardiovascular risk factors; Group II: subjects with dyslipidaemia with at least 1 additional cardiovascular risk factor, excluding CHD and DM; Group III: subjects with dyslipidaemia with CHD or CHD risk equivalent.

                        b A history of premature coronary heart disease in a first-degree relative (parent or sibling). If the afflicted family member was male, premature coronary heart disease would have occurred before age 55, and if female, before age 65.

                        At the end of the study, the ITT set consisted of data from 132 and 131 subjects, from the intervention and control arms respectively. At week 24, there was a trend towards greater improvement in the intervention group. The least squares (LS) mean changes from baseline LDL-C were −30.09% and −27.54% for the intervention group and control groups, respectively. The difference of mean change in the intervention group was 2.55% lower than the control group, however this was not significant (p=0.288). At week 36, the LS mean of LDL-C between the 2 study arms was comparable at −25.88 and −26.86, for the intervention and control groups respectively. On the other hand, there was a statistically significant difference when comparing the LS mean in the intervention arm at week 24 and week 36 (p=0.016). This was due to withdrawal of the COACH programme which resulted in a diminution of the earlier LDL-C improvements seen in the intervention arm.

                        Similar outcomes were observed with total cholesterol (TC) level. The trend towards improved TC seen in the intervention group compared with the control arm at 24 weeks did not sustain at 36 weeks. No significant difference was detected in triglyceride (TG) levels at week 24 and 36 between the 2 study arms. Table 2 and 3 illustrates the percentage change from baseline in LDL-C and TC between the intervention and control group.
                        Table 2

                        Percent change from baseline in LDL-C, TC and HDL-C between intervention and control groups

                        Time point


                        LS Mean (SE)

                        Difference in LS Means (%)

                        PCP-NE (n=132)

                        PCP (n=131)

                        PCP-NE versus PCP

                        95% Cl (%)


                        Week 24


                        −30.09 (2.03)

                        −27.54 (2.03)


                        −7.26, 2.16



                        −22.97 (1.55)

                        −20.80 (1.54)


                        −5.72, 1.38



                        −2.60 (1.30)

                        −5.61 (1.30)


                        0.12, 5.90


                        Week 36


                        −25.88 (2.03)

                        −26.86 (2.03)


                        −3.68, 5.65



                        −19.94 (1.53)

                        −19.97 (1.52)


                        −3.43, 3.51



                        −2.97 (1.42)

                        −5.44 (1.41)


                        −0.79, 5.74


                        LS = Least Squares; SE = Standard Error; 95%; CI = 95% Confidence Interval; LDL-C = Low Density Lipoprotein Cholesterol; TC = Total Cholesterol; HDL-C = High Density Lipoprotein Cholesterol; PCP = Primary Care Physicians; PCP-NE = Primary Care Physicians assisted by Nurse Educators.

                        Table 3

                        Percent change from baseline in LDL-C, TC and HDL-C between week 24 and 36

                        Study Arm


                        LS Mean (SE)


                        Week 24

                        Week 36

                        PCP-NE (n=132)


                        −30.09 (2.03)

                        −25.88 (2.03)



                        −22.97 (1.55)

                        −19.94 (1.53)



                        −2.60 (1.30)

                        −2.97 (1.42)


                        PCP (n=131)


                        −27.54 (2.03)

                        −26.86 (2.03)



                        −20.80 (1.54)

                        −19.97 (1.52)



                        −5.61 (1.30)

                        −5.44 (1.41)


                        LS = Least Squares; SE = Standard Error; 95% CI = 95% Confidence Interval; LDL-C = Low Density Lipoprotein Cholesterol; TC = Total Cholesterol; HDL-C = High Density Lipoprotein Cholesterol; PCP = Primary Care Physicians; PCP-NE = Primary Care Physicians assisted by Nurse Educators.

                        In contrast, a significant difference was detected in high density lipoprotein-cholesterol (HDL-C) at week 24 between the intervention and control group with a greater decrease in HDL. As illustrated in Table 2, the difference in LS means of HDL-C between the intervention and control group was 3.01 (95% CI 0.12 – 5.90), p=0.041 at week 24. However, this effect did not persist beyond the duration of the intervention (p=0.136) after week 24 (Table 3). These results at and after week 24 were also reflected similarly in the total cholesterol (TC): high-density lipoprotein cholesterol (HDL-C) ratio.

                        There were no significant differences between both study arms in relation to statin treatment compliance, systolic and diastolic blood pressure and Framingham Coronary Heart Disease risk scores at week 24. In terms of lifestyle modification (i.e. cigarettes smoking, dietary changes, and physical activity), no difference was observed between the intervention and control group. In general, more than 80% of the subjects were satisfied with the health booklet provided. Approximately 90% of subjects from the intervention arm also expressed satisfaction with the programme in helping them achieve health care goals through telephone follow-up by nurse educators.


                        The COACH programme in this study utilised patient education and empowerment as well as decision support as interventional strategies to improve cholesterol control. Both study arms had shown improved LDL-C and TC level throughout the study period. The results were a trend towards add-on improvements in both LDL-C and TC levels when patients were co-managed by nurse educators, even though this was not statistically significant.

                        The lack of statistical significance was most likely attributed to dilution of treatment effects with the use of similar patient education methods in the control group as well as in the intervention group, specifically, using the COACH health booklet. The COACH programme applied in our study delivered more comprehensive care than usual compared to the typical Malaysian primary care settings, which usually have little time or resource to provide comprehensive disease management care as part of daily practices [19]. As a result, in this study, patients from both study arms would have benefited from increased knowledge of their health conditions.

                        Although the COACH programme used in this study was similar to other studies published by Vale et al. [16] and Allen et al. [17], there are significant differences in terms of study methodology. In the study conducted Vale et al. [16], patients were continuously coached based on previous assessment visit and progress monitored via negotiated action plan. In addition, the Vale’s study focused on hospital based disease management programme. On the other hand, the COACH programme by Allen et al. [17] utilised the model of community-based participatory research methodology to design the disease management programme, which consisted of enhanced usual care with or without intensive disease management by nurse practitioner/community health workers. Both studies had adopted many essential elements from the Chronic Care Model [3], which had been proven to improve chronic disease outcomes. In contrast to this study, the authors had only adapted the previous COACH studies as a patient support programme rather than a disease management programme due to severe resource limitation i.e. lack of trained nursing support resulting in resistance from local doctors to adopt a shared-care model on patient disease management counselling. As a result, the nurse educators in this study had no access to patient’s medical records and health education was reinforced using the health education booklet only.

                        Evidence for the success of disease management programmes involving additional support from nurses or other disciplines is mixed. Our findings are comparable with some studies [14, 20] where reduction in blood cholesterol was similarly equivocal due to the Hawthorne effect among patients and healthcare providers, a change in people’s behaviour when being observed. In addition, the study may have heightened the awareness of disease management practices among family physicians involved. However, studies published by Vale et al. [16] and Allen et al. [17] that utilised a similar programme, demonstrated significant improvement in LDL-C and TC change from baseline when patients with coronary heart diseases underwent the programme. As opposed to our study, the positive outcomes demonstrated in both the studies may be due to: (1) the population enrolled i.e. the study recruited CHD patients experiencing acute coronary syndrome who were more motivated to change; (2) difference in setting i.e. developed versus developing country; (3) difference in prescription behaviour i.e. higher proportion of patients prescribed with statin and with higher doses of atorvastatin in the Vale et al. study (not commonly prescribed among the doctors in the DISSEMINATE study). Besides the 2 studies discussed above, there are also other studies that have had positive results with multi-disciplinary support [2124].

                        The DISSEMINATE study had also revealed interesting findings with regards to HDL-C decrease over the 6 months duration. This finding was inconsistent with many clinical studies that reported mild improvement of HDL-C with both drug treatment and disease management care [25, 26]. Several theories are hypothesised for this outcome. First of all, there is some evidence that a low fat diet reduces not just LDL-C but also HDL-C [2729]. Secondly, the COACH programme did not provide detailed nutritional education with information on how to reduce high dietary fat intake while substituting dietary fat with polyunsaturated fatty acids (PUFA) such as olive oil. It is possible that both of these factors could have resulted in the unexpected reduction in HDL-C levels detected in our study.

                        Several limitations to our study are identified. In an effort to standardise patient care between different sites, a health booklet was distributed to all subjects. As discussed above, this had diluted the difference in interventional effects between control group and intervention group. Also, the findings in the control arm would not be generalise to the current primary care settings as it had deviated from the normal local practice; however, the outcomes from this study has demonstrated that current chronic disease care in Malaysia primary care practices are suboptimal and some improvements in patient’s disease outcome can be achieved by simply spending extra time to educate the patients on chronic disease self-management and treatment compliance. And furthermore, our study has also shown that the task of personalised patient education does not have to be purely the domain of the physicians but can also be provided by trained nurses. The study might have elicited a more significant finding with addition of a third study arm assessing the lipid outcomes among patients who received “actual” standard care delivery by local physicians. Though the primary outcome of the study was not achieved, an additional post-hoc analysis may be able to determine the proportion of uncontrolled dyslipidaemic patients who achieved cholesterol target at the end of the study follow-up. In the current analysis, the proportion of patients who achieved target cholesterol level is not known. A higher than expected attrition rate (initial sample size calculation only accounted for 10% loss to follow-up) could have also affected the final results of the study.

                        Although our study showed that complementary nurse support services in a disease management programme had a positive trending impact on LDL-C and TC level compared to physician management alone, the effect was not sustainable after the intervention was withdrawn at week 24. Continuous therapeutic behavioural change seems to be mandated to ensure long-term sustainable lipid control.


                        This study was designed as a trial in a “real-world” setting and thus faced with its share of expected challenges. The limitations of our study are acknowledged, and some of the lack of effect may be attributable to similarities between the management of patients in the intervention and control group. Further study would be warranted to build upon the results of this study while addressing some of the limitations. Despite the lack of statistical significance, the trend towards improved dyslipidaemia can be considered a success at some level. As there is a paucity of published evidence on disease management programmes in this region, the data provided by this study may be considered an indicator about the potential role of disease management programmes in developing Asian countries.



                        Adverse events


                        Adult Treatment Panel


                        Body mass index


                        Blood pressure


                        Chronic Disease Management


                        Coronary heart disease


                        Confidence interval




                        Counselling and Advisory Care for Health


                        Community based cardiovascular risk factor intervention strategy


                        Case report form


                        Disease management programme on the attainment of better cardiovascular risk control


                        Diabetes mellitus




                        End stage renal disease


                        Full analysis set


                        Good Clinical Practice


                        General practitioner


                        High density lipoprotein cholesterol




                        International Conference on Harmonization




                        Low density lipoprotein cholesterol


                        Least squares


                        Milligram per deciliter


                        Millimol per liter


                        Millimeter mercury


                        Mixed model repeated measures


                        Medical Research Ethical Committee


                        National Cholesterol Education Program


                        National Institute of Health


                        Polyunsaturated fatty-acid


                        Restricted maximum likelihood model


                        Standard deviation


                        Standard error


                        Short messaging service


                        Total cholesterol




                        Visual analogue scale


                        World Health Organization.



                        The authors would like to thank the following individuals for their contribution in the study, Dr Arup Pramanik, Dr Wong Kok Seng, Dr Alaster Allum and Dr Vicknesh Welluppillai for the guidance in preparation of the protocol and interim management of the study; Pfizer’s clinical research team for their consistent effort in maintaining the data quality of this study; all the other DISSEMINATE study investigators (Harjit Singh Gendeh, Habshoh Hat, A Vickneswari Ayadurai, Anandan Subramaniam, Norsiah Md Noor, Zil Falillah Mohd Said, Mohd Faudzi Abdullah, Inthirani M Sivarajah, Sofiah Zainal Abidin, Prakash S Gurusamy, Ravinder Singh Dhillon, Sanjay Lalitchandra Doshi) for their contribution in patient recruitment. The authors’ gratitude also extends to all individuals who have directly or indirectly contributed to the successful execution of the study.

                        Authors’ Affiliations

                        Eli Lilly (M) Sdn Bhd, E1-2 Puncak Arabella
                        Hospital University Science Malaysia
                        National University Medical Center
                        Polyclinic & Surgery Ayer Molek
                        Nilai Health Clinic
                        Awana Kijal Clinic
                        Tampin Health Clinic
                        Kapar Clinic
                        Bagan Serai Health Clinic
                        Azmi Burhani Consulting


                        1. World Health Organization: Preventing chronic diseases: a vital investment: WHO global report. Geneva: WHO Press; 2005.
                        2. Nugent R: Chronic diseases in developing countries: Health and economic burdens. Ann N Y Acad Sci 2008, 1136:70–79.PubMedView Article
                        3. World Health Organization: Innovative care for chronic conditions: building blocks for action. Geneva: WHO Press; 2002.
                        4. Beaglehole R, Epping-Jordan J, Patel V, Chopra M, Ebrahim S, Kidd M: Improving the prevention and management of chronic disease in low-income and middle-income countries: a priority for primary health care. Lancet 2008, 372:940–949.PubMedView Article
                        5. Epping-Jordan J, Pruitt S, Bengoa R, Wagner E: Improving the quality of health care for chronic conditions. Qual Saf Health Care 2004, 13:299–305.PubMedView Article
                        6. Ofman J, Badamgarav E, Henning J, Knight K, Gano A, Levan R, Gur-Arie S, Richards MS, Hasselblad V, Weingarten SR: Does disease management improve clinical and economic outomces in patients with chronic diseases? A systematic review. Am J Med 2004, 117:182–192.PubMedView Article
                        7. Shekelle P, Maglione M, Chodosh J, Mojica W, Morton SC, Suttorp MJ, Roth EA, Rhodes S, McKinnon E, Wu S-Y, Rubenstein L, Lapin P: Chronic disease self-management for diabetes, osteoarthritis, post-myocardial infarction care and hypertension. Santa Monica: RAND Corporation; 2004.
                        8. Tsai A, Morton S, Mangione C, Keeler E: A meta-analysis of interventions to improve care for chronic illnesses. Am J Mang Care 2005, 11:478–488.
                        9. Zwar N, Harris M, Griffiths R, Roland M, Dennis S, Powell Davies G, Hasan I: Systematic review of chronic disease management. Sydney: Research Centre for Primary Health Care and Equity; 2006.
                        10. Yusoff AF, Mustafa AN, Kaur G, Omar MA, Vos T, Rao VPC, Begg S: Malaysian burden of disease and injury study 2005. Kuala Lumpur: Institute of Public Health, National Institutes of Health Malaysia; 2005.
                        11. Malaysia Ministry of Health: National Health Morbidity Survey III. Kuala Lumpur: Institute of Public Health Malaysia; 2008.
                        12. Ramli A, Taher S: Managing chronic diseases in the Malaysian primary health care - a need for change. Malaysian Family Physician 2008,3(1):7–13.
                        13. Low W: Panel discussion: chronic disease management in private general practice: what is the future? Malays Fam Physician 2010,5(1):57–58.
                        14. Lapointe F, Lepage S, Larrivee L, Maheux P: Surveillance and treatment of dyslipidaemia in the post-infarct patient: can a nurse-led management approach make a difference? Can J Cardiol 2006,22(9):761–767.PubMedView Article
                        15. New JP, Mason JM, Freemantle N, Teasdale Sue , Wong LM, Bruce NJ, Burns JA, Gibson JM: Specialist nurse-led intervention to treat and control hypertension and hyperlipidemia in diabetes (SPLINT): a randomized controlled trial. Diabetes Care 2003, 26:2250–2255.PubMedView Article
                        16. Vale M, Jelinek M, Best J, Dart A, Griggs L, Hare D, Ho BP, Newman RW, McNeil JJ: Coaching patients on achieving cardiovascular health (COACH): a multicenter randomized trial in patients with coronary heart disease. Arch Intern Med 2003, 163:2775–2783.PubMedView Article
                        17. Allen JK, Dennison-Himmerlfarb CR, Szanton SL, Bone L, Hill MN, Levine DM, Barlow A, Lewis-Boyer LP, Donnelly-Strozzo M, Curtis C, Anderson K: Community Outreach and Cardiovascular Health (COACH) trial: a randomized, controlled trial of nurse practitioner/community health worker cardiovascular disease risk reduction in urban community health centers. Circ Cardiovasc Qual Outcomes 2011, 4:595–602.PubMedView Article
                        18. National Institute of Health (NIH): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Final Report. Bethesda: NIH Publication; 2002.
                        19. Zailinawati AH, Tong SF, Nordin S, Lee VKM, Mimi O, Khoo EM, Chen WS, Teng CL: Malaysia primary care providers characteristics and workload: the national primary care survey. Malays Fam Physician 2009,4(supp 2):48–49.
                        20. Ammerman A, Keyserling T, Atwood J, Hosking J, Zayed H, Krasny C: A randomized controlled trial of a public health nurse directed treatment program for rural patients with high blood cholesterol. Prev Med 2003,36(3):340–351.PubMedView Article
                        21. McPherson CP, Swenson KK, Pine DA, Leimer L: A nurse-based pilot program to reduce cardiovascular risk factors in a primary care setting. Am J Mang Care 2002, 8:543–555.
                        22. Allen JK, Blumenthal RS, Margolis S, Young DR, Miller ER III, Kelly K: Nurse case management of hypercholesterolemia in patients with coronary heart disease: results of a randomized clinical trial. Am Heart J 2002, 144:678–686.PubMed
                        23. Tsuyuki RT, Johnson JA, Teo KK, Simpson SH, Ackman ML, Biggs RS, Cave A, Chang WC, Dzavik V, Farris KB, Galvin D, Semchuk W, Taylor JG: A randomized trial of the effect of community pharmacist intervention on cholesterol risk management (SCRIP). Arch Intern Med 2002, 162:1149–1155.PubMedView Article
                        24. DiTusa L, Luzier AB, Brady G, Reinhardt M, Snyder BD: A pharmacy-based approach to cholesterol management. Am J Manag Care 2001, 7:973–979.PubMed
                        25. Kapur NK, Ashen D, Blumenthal RS: High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease. Vasc Health Risk Manag 2008,4(1):39–57.PubMedView Article
                        26. Barter PJ, Brandrup-Wognsen G, Palmer MK, Nicholls SJ: Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER database. J Lipid Res 2010, 51:1546–1553.PubMedView Article
                        27. Berglund L, Oliver EH, Fontanez N, Holleran S, Matthews K, Roheim PS, Ginsberg HM, Ramakrishnan R, Lefevre M: HDL-subpopulation patterns in response to reductions in dietary total and saturated fat intakes in healthy subjects. Am J Clin Nutr 1999, 70:992–1000.PubMed
                        28. Asztalos B, Lefevre M, Wong L, Foster TA, Tulley R, Windhauser M, Zhang WW, Roheim PS: Differential response to low-fat diet between low and normal HDL-cholesterol subjects. J Lipid Res 2000, 41:321–328.PubMed
                        29. Brinton EA, Eisenberg S, Breslow JL: A low-fat diet decreases high density lipoprotein (HDL) cholesterol levels by decreasing HDL Apolipoprotein transport rates. J Clin Invest 1990, 85:144–151.PubMedView Article
                        30. Pre-publication history

                          1. The pre-publication history for this paper can be accessed here:http://​www.​biomedcentral.​com/​1471-2296/​13/​97/​prepub


                        © Selvaraj et al.; licensee BioMed Central Ltd. 2012

                        This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.